A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Jemal, 2007, Cancer statistics, 2007, CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43 Butler, 2000, Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo, Cancer Res, 60, 5165 Butler, 2002, The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin, Proc Natl Acad Sci U S A, 99, 11700, 10.1073/pnas.182372299 Chobanian, 2004, Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status, Anticancer Res, 24, 539 Desimone, 2003, The combined in vitro effects of paclitaxel and histone deacetylase inhibitors on ovarian cancer, Proc Am Assoc Cancer Res, 44, 217 Dietrich, 2006, Suberoylanilide hydroxamic acid potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines, Gynecol Oncol, 101, S149 Greenberg, 2001, Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells, Thyroid, 11, 315, 10.1089/10507250152039046 Richon, 2001, Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers, Blood Cells Mol Dis, 27, 260, 10.1006/bcmd.2000.0376 Sonnemann, 2006, Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients, BMC Cancer, 6, 183, 10.1186/1471-2407-6-183 Sonnemann, 2006, Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells, Cancer Lett, 232, 148, 10.1016/j.canlet.2005.02.009 Richon, 2006, Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor, Br J Cancer, 1, S2, 10.1038/sj.bjc.6603463 Duvic, 2003, Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), Blood, 102 Kelly, 2003, Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously, Clin Cancer Res, 9, 3578 Cooper, 2007, In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer, Gynecol Oncol, 104, 596, 10.1016/j.ygyno.2006.09.011 Manetta, 1998, Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group, Gynecol Oncol, 68, 45, 10.1006/gyno.1997.4887 Markman, 1998, Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial, Gynecol Oncol, 69, 226, 10.1006/gyno.1998.5016 Plaxe, 2002, A phase II trial of pyrazoloacridine (PZA) in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study, Am J Clin Oncol, 25, 45, 10.1097/00000421-200202000-00009 Fracasso, 2001, Phase II study of paclitaxel and VALSPODAR (PSC 833) in refractory ovarian carcinoma: a Gynecologic Oncology Group study, J Clin Oncol, 19, 2975, 10.1200/JCO.2001.19.12.2975 Hoffman, 2000, Phase II trial of CI-958 in recurrent, platinum-refractory ovarian carcinoma: Gynecologic Oncology Group study, Gynecol Oncol, 79, 463, 10.1006/gyno.2000.5984 Markman, 1999, Lack of efficacy of 24-hour infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial, Gynecol Oncol, 75, 444, 10.1006/gyno.1999.5640 Fracasso, 2003, Phase II study of oxaliplatin in platinum resistant and refractory ovarian cancer: a Gynecologic Oncology Group study, J Clin Oncol, 21, 2856, 10.1200/JCO.2003.03.077 Takai, 2004, Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis, Cancer, 101, 2760, 10.1002/cncr.20709 Chen, 1998, Optimal flexible designs in phase II clinical trials, Stat Med, 17, 2301, 10.1002/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X Bolden, 2006, Anticancer activities of histone deacetylase inhibitors, Nat Rev Drug Discov, 5, 769, 10.1038/nrd2133 Kelly, 2005, Drug insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid, Nat Clin Pract Oncol, 2, 150, 10.1038/ncponc0106 Gabrielli, 2004, Defining the chemotherapeutic targets of histone deacetylase inhibitors, Ann N Y Acad Sci, 1030, 627, 10.1196/annals.1329.073 Kelly, 2005, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer, J Clin Oncol, 23, 3923, 10.1200/JCO.2005.14.167 Mehnert, 2007, Histone deacetylase inhibitors: biology and mechanism of action, Cancer J, 13, 23, 10.1097/PPO.0b013e31803c72ba Marrocco, 2007, Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation, Mol Cancer Ther, 6, 51, 10.1158/1535-7163.MCT-06-0144 Duvic, 2007, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, 109, 31, 10.1182/blood-2006-06-025999